Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, administered as a once-weekly subcutaneous injection for obesity and type 2 diabetes
A 2023 observational study in Clinical Gastroenterology and Hepatology found that patients on GLP-1 therapy for metabolic conditions reported a 32% reduction in GERD symptom frequency versus controls
He suggests his patients start with 300 to 600 milligrams of glutathione (I got 300 milligrams) three times a week
To further study this phenomenon, the team performed a small, randomized, and controlled trial with 30 patients who had obesity and obstructive sleep apnea, or OSA
Considerations: Although you can alter what vitamins are sent to you, the personalized subscription may wind up being more costly than buying the supplement solo
Pritikin Program Lon Ben-Asher, Registered Dietitian and Pritikin Educator Prevent GI Side Effects Effective strategies to reduce gastrointestinal side-effects of GLP-1 drugs exist